Trial Information

Summary: PHI-50 NCI#6432: A Phase I Pharmacokinetic Study of PS-341 in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group

You have been asked to participate in this research study because you have advanced cancer that is no longer responding to standard treatment and your liver function is normal or is no longer normal.  The purpose of this research study is to find out the highest dose of an experimental drug PS-341 that can be given to subjects with advanced cancer and abnormal liver function without causing unmanageable side effects.  Additionally, researchers will be looking to find out how the study drug moves through the body.  You can continue taking the drug until your tumor grows, until severe side effects occur, or you withdraw your consent.  After your treatment is over, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:31:14 PM